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ABSTRACT 
Current recommended treatment of chronic hepatitis C is the combination of peg interferon 
and ribavirin. Ribavirin has shown that it poses both direct and indirect action mechanisms 
against several DNA and RNA viruses. Interferon is a potent immune modulating substance, 
but its effect on the immune system of HCV-infected patients during treatment is not known 
in detail. It has been shown that interferon induces a significant increase in total IgG and C1 
inhibitor (INH) in patients with MS.  
The primary aim of this work was to study the effects of the combination therapy on the 
immunoglobulin levels. More specifically to see whether, the increased IgG levels were 
primarily due to HCV antibodies or whether antibodies to other viruses such as adenovirus, 
measles virus, and rubella virus are also increased. Sera from 24 patients in the 
NORDynamIC study at Haukeland University Hospital between February 2004 and March 
2006 were used.  Combination therapy with ribavirin and peginterferon was given for 12 or 
24 weeks. Total IgG level, anti-HCV level, and antibodies to rubella, adeno and morbilli 
viruses were studied at different time points over 48 weeks. 
Total IgG level was fluctuating during the period of study. The highest level of IgG was found 
at day 8 whereas the lowest level was found at week 8 of treatment. Those who responded to 
the combination therapy showed a declining level of total IgG even after cessation of therapy 
while the non-responders showed an increased level og IgG after cessation of therapy.  The 
relationship between IgG and anti-HCV levels showed the same pattern in responders 
whereas in non-responders total IgG show considerable variation and did not follow anti-
HCV levels as observed in responders. All patients were anti-rubella IgG positive and there is 
a correspondence between the mean rubella antibody levels and mean IgG levels both in 
responders and non-responders. Most of the sera had no reactivity to either adeno virus or 
morbilli virus and there was no correspondence between antibody levels for morbilli or adeno 
viruses and total IgG.  
The study concludes that there seems to be an effect of combination therapy on total IgG and 
total IgG levels corresponds well with the anti-HCV antibody levels in responders. Rubella 
antibody was increased in all chronic HCV patients in the study and seems to have 
relationship with the total IgG level. Antibodies to adeno and morbilli viruses were not 
influenced by the treatment. 
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1. INTRODUCTION 
 
1.1 Hepatitis C virus 
Hepatitis C virus (HCV) is a small, enveloped RNA virus belonging to the Flaviviridae family 
genus Hepacivirus. HCV infects only humans and chimpanzees and causes acute and chronic 
liver disease in humans, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma 
(HCC). 
 
1.1.1 HCV structure and genome 
The HCV genome is a single-stranded RNA molecule of positive polarity. It contains one 
single open reading frame (ORF) encoding a polyprotein of about 3,000 amino acids (Fig. 1). 
The ORF is flanked by 5´ and 3´ nontranslated regions (NTR) and contain highly conserved 
RNA structures essential for polyprotein translation and genome replication. The 5´ NTR 
contains an internal ribosome entry site (IRES) that binds the 40S ribosomal subunit and 
initiates polyprotein translation in a cap-independent manner. The polyprotein precursor is co-
translationally and post-translationally processed by both cellular and viral proteases at the 
level of the endoplasmic reticulum (ER) membrane to yield 10 mature proteins [1]. The 
structural proteins include the core (C), which forms the viral nucleocapsid, and the envelope 
glycoproteins E1 and E2. They are released by host-cell signal peptidases. The structural 
proteins are separated from the nonstructural (NS) proteins by the short membrane peptide p7, 
which is a viroporin. The nonstructural proteins NS2 to NS5B are involved in polyprotein 
processing and viral replication. The proteolytic processing of NS part of polyprotein requires 
the NS2-NS3 zinc-dependent metalloproteinase and the NS3 serine proteinase. The NS2-NS3 
proteinase appears to cleave at the NS2/NS3 site by a conformation-dependent, autocatalytic 
mechanism [2]. The NS3 proteinase with its cofactor NS4A releases the remaining NS 
proteins. The C-terminal region of NS3 protein includes RNA helicase and NTPase activities. 
Both NS4B and NS5A are membrane associated proteins. NS5A has three domains where 
domain I has cystein residues essential for RNA replication, domain II is involved in 
inhibition of the IFN induced double stranded RNA activated protein kinases PKR and 
domain III is less conserved where deletions and insertions can occur. NS5B is an RNA-
dependent RNA polymerase (RdRp) and activity is modulated by interactions by NS3 and 
NS5A. [3-7]  
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Figure1. Hepatitis C virus: model structure and genome organisation. (a) Model structure of HCV. The left-
hand side of the illustration shows the viral surface of envelope lipids and glycoproteins; the right-hand side 
shows the RNA genome enveloped by capsid proteins. (b) Proteins encoded by the HCV genome. Putative 
functions of the cleavage products are shown [8]. 
 
1.1.2 Genotypes 
Genetic differences between HCV isolates are used to classify HCV into genotypes and 
subtypes. There are six genotypes (1-6) and more than 70 subtypes (a,b, c, etc) termed as 
isotypes or quasispecies. The genotypes differ in 30-35% of neucleoside sites, of the genome 
and most of the variability occurs in the ‘hypervariable’ regions (HVRs) found in the E1 and 
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E2 glycoproteins. Sequences of the core gene and some of the non-structural protein genes, 
such as NS3, are more conserved. Between the six genotypes the lowest sequence variability 
is found in the 5´ NTR [9]. All HCV genotypes have a common ancestor virus. Distribution of 
HCV genotypes varies globally. For example, in North America, genotype 1a predominates 
followed by 1b, 2a, 2b, and 3a. In Europe, genotype 1b is predominant followed by 2a, 2b, 2c, 
and 3a. Genotypes 4 and 5 are found almost exclusively in Africa. The genotype is clinically 
important in determining potential response to interferon-based therapy and the required 
duration of such therapy. Furthermore, infection with one genotype does not confer immunity 
against others, and concurrent infection with two strains is possible. In most of these cases, 
one of the strains removes the other from the host in a short time [10].  
 
1.1.3 Life cycle 
The HCV life cycle is poorly known because of the lack of a productive culture system which 
is established very recently [11]. Hepatocytes are the main replication site for HCV, although 
studies have shown replication in B cells, dendritic cells (DC), and other peripheral blood 
mononuclear cells. [11]. 
HCV entry seems to be a complex multistep process that starts with virion attachment to its 
specific cell surface protein receptors. The recent studies have identified several of them such 
as, CD81, scavenger receptor class B type I (SR-BI) occulidin and claudin-1. The exact role 
of each molecule involved in HCV entry is not clear yet. Further additional accessory factors 
like glycosaminoglycans (GAGs) and the low density lipoprotein receptor (LDLR) are 
involved in the initial attachment. After the initial binding step, the particle interacts with SR-
BI and CD81 (fig 2). Virions bound to SR-BI and CD81 are transported to the tight junction. 
Contact with the occludin and claudin-1 at tight junction is the final keys for viral entry. Then 
the HCV is internalized by clathrin-mediated endocytes and fusion probably occurs in early 
endosomes [12]. After the decapsidation, the genomic HCV RNA is replicated and translated 
in the cytoplasm. Replication and post-translational processing appear to take place in 
the"replication complex", located in close contact with perinuclear membranes. Genome 
encapsidation appears to take place in ER and nucleocapsids are enveloped and matured in the 
Golgi apparatus. Newly produced virions are released in the pericellular space by exocytosis 
[13, 14].  
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Figure 2: Circulating HCV particles can be associated with low- and very-low-density lipoproteins (LP). Virus 
binding to the cell surface and entry may involve the low density lipoprotein receptor (LDLR), 
glycosaminoglycans (GAG), scavenger receptor class B type I (SR-BI), the tetraspanin protein CD81 and 
claudin-1 (CLDN1 [15]. 
 
1.2 Natural history of Heapatitis C infection 
The World Health Organization estimates that about 3% of the world population is infected 
with HCV and 3-4 million new infections occur each year. A Norwegian survey showed 
0,13% anti-HCV positivity among new blood donors, 0,7% in pregnant women and in the 
general adult population prevalence was 0,55% [16]. In high risk groups like active drug users 
and past drug users the prevalence is 70%. This means Norway can have 20 000-30 000 HCV 
infected persons and HCV has the largest share among the hepatotrophic viruses found in 
Norway.  
The rate of chronic HCV infection is influenced by a person's age, gender, race, and viral 
immune response. Approximately 75%-85% of HCV infected persons progress further to 
chronic HCV infection with risk for the development of extrahepatic manifestations, 
compensated and decompensated cirrhosis, and hepatocellular carcinoma. The transmission of 
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HCV is primarily through exposure to blood. Other risk factors include intravenous drug use, 
high-risk sexual activity, solid organ transplantation from an infected donor, occupational 
exposure and haemodialysis [17]. 
 
1.2.1 Acute infection 
Acute hepatitis C infection is infrequently diagnosed because the majority of acutely infected 
individuals are asymptomatic and these account for about 20% of acute hepatitis. Of adults 
with acute HCV infection 20-30% may develop clinical symptoms. Onset of symptoms ranges 
from 3 to 12 weeks after exposure. Symptoms may include malaise, weakness, anorexia, and 
jaundice. Incubation period is on average 50 days but it can vary from 15 to 150 days [17]. 
 
1.2.2 Chronic infection 
Chronic hepatitis C infection is marked by the persistence of HCV RNA in the blood for at 
least 6 months after onset of acute infection. HCV is self-limiting in only 15%-25% of 
patients in whom HCV RNA in the serum becomes undetectable and alanine amino tranferase 
(ALT) levels return to normal. Approximately 75%-85% of HCV infected persons will 
progress to chronic HCV infection and are at risk for advanced liver fibrosis, HCV-related 
extrahepatic complications, cirrhosis and HCC. Risk factors for developing chronic infections 
are age >25 yrs, male gender, no symptoms during acute infection, African American race, 
HIV infection and immune suppression. Chronic infection is often asymptomatic. An 
estimated 10%-20% of chronic HCV infections advance to end-stage liver disease over one or 
two decades. Extrahepatic manifestations involving multiple organ systems can occur during 
chronic HCV infection or cirrhosis, but HCC appears to develop only after cirrhosis [17]. 
 
1.3 Immune response during HCV infection 
Viral RNA appears in the peripheral blood within 1-2 weeks of HCV exposure, and triggers 
both the innate and the adaptive immune responses [11]. 
 
1.3.1 Early control of HCV infection 
1.3.1.1 The Innate Immune Response 
Rapid and efficient activation of the different components of the innate immune system is 
crucial not only for the initial containment of virus replication and spread, but also for a 
timely and efficient promotion of downstream adaptive responses. Adaptive responses require 
more time for their induction but are essential for complete and persistent control of infection. 
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HCV RNA triggers the production of type 1 interferon (IFN) α / β and activation of multiple 
IFN responsive genes in infected cells. IFN also inhibits replication of viruses and induce 
apoptosis in infected hapatocytes in addition to upregulate the expression of HCV antigens on 
the surface of infected hapatocytes. Natural Killer cells (NK cells) contribute to the control of 
viral replication through cytolysis of infected cells, induction of replication inhibitory 
cytokines like IFN and activation of both Dentritic (DC) and T cells. DCs play an important 
role as antigen presenting cells and link innate and adaptive immune response [18, 19]. 
 
1.3.1.2 Adaptive Immune Response 
Development of neutralizing antibodies is a hallmark of clearance in many viral infections. 
HCV-specific antibodies usually become detectable in the serum within several weeks after 
the primary infection and they appear after cellular immune responses and ALT elevations. 
The first detectable antibodies against HCV antigens in serum usually target NS3 protein 
(anti-c33 Ab) and core protein (anti-capsid or anti-22c Ab). Later, the specific antibodies 
against NS4 protein and envelope glycoproteins (E1 and E2) appear [20]. 
A number of studies have indicated that successful cellular immune responses in recovered 
patients appear to be multispecific and sustained; with CD4+ T cells playing major roles. 
CD4+ T cells have antiviral responses, both via secreting antiviral cytokines from HCV-
specific type 1 helper T cell and via activation of B cells and CD8+ T cells. Vigorous and 
sustained HCV-specific CD4+ and CD8+ T cell responses against multiple HCV epitopes are 
necessary for spontaneous viral clearance during the acute phase. The definitive role of CD4+ 
T cell responses in acute HCV infection was shown in a recent study where in absence of 
CD4+ T cell responses, HCV-specific CD8+ T cell and neutralizing antibodies may develop, 
but fail to control viremia [21]. CD8+ T cells could respond to HCV viral infection through 
two main mechanisms: the killing of infected hepatocytes or the secretion of antiviral 
cytokines. Studies have indicated that CD8+ T cells are primarily effector cells mediating 
protective immunity, while CD4+ T cell help is required for CD8+ T cells to keep pace with 
the evolution of viral escape mutants [11, 19].  
 
1.3.2 Immune escape 
HCV has developed several escape mechanisms to evade host´s immune systems. In addition 
to interference with the endogenous IFN system and DC dysfunction, there is evidence for 
viral evasion of the adaptive immune response. Loss of CD4+ T cells during early infection is 
one mechanism of persistence in HCV infection. Others have shown that HCV-specific CD8+ 
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T cells in chronic infection are functionally impaired with respect to IFNγ production [22-24] 
and, it is consistent with loss of CD8+ function [25]. Mutational escape from adaptive 
immune response has been suggested to be one of the evasion strategies used by HCV. The 
mutation rate of HCV is high due to the lack of proofreading capacity of its polymerase. This 
property helps HCV to escape T- and B-cell surveillance by mutating residues relevant to T- 
and B-cell recognition. HCV is able to acquire an early survival advantage over the host 
immune system due to its fast replication kinetics and its capacity to interfere with the early 
intracellular pathways of antiviral defence. These intrinsic features of the virus may also 
impact on priming and maturation of adaptive responses through T-cell exhaustion, 
mutational escape from T- and B-cell surveillance, and negative modulation of the early 
cross-talk between innate and adaptive immunity, providing the virus with an additional 
survival advantage that can contribute to the high rate of HCV persistence. Classic cytotoxic 
T cells (CTL) may primarily damage the liver in chronic HCV, but there may be 
subpopulations of T cells that protect against liver inflammation [19]. 
 
1.4 Diagnostic tools for HCV infection 
1.4.1 Serological assays 
The detection of anti-HCV antibodies in plasma or serum is based on the use of third-
generation EIAs (example: Axsym, Abbott systems), which detect mixtures of antibodies 
directed against various HCV epitopes. Recombinant antigens are used to capture circulating 
anti-HCV antibodies. The specificity of third-generation EIAs for anti-HCV is greater than 
99%. Their sensitivity is more difficult to determine, given the lack of a gold standard 
method, but it is excellent in HCV-infected immunocompetent patients [26]. 
 
1.4.2 Detection of HCV RNA 
1.4.2.1 Qualitative Tests 
Qualitative detection assays are based on the principle of target amplification using either 
“classic” polymerase chain reaction (PCR), “real-time” PCR or transcription-mediated 
amplification (TMA) [27]. Qualitative tests are used to confirm viremia. Moreover, these tests 
also have clinically important applications in predicting patients at risk for virological relapse 
once therapy stops and in diagnosing acute HCV infection [28, 29]. 
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1.4.2.2 Quantitative tests 
There are 3 types of tests to quantify HCV RNA: quantitative reverse transcription–PCR 
(Monitor® Roche Diagnostics), real-time PCR (Cobas Amplicor® Roche Diagnostics, Abbott 
Diagnostic), and branched-chain DNA (bDNA) ( Versant® Bayer Health care) [30].  
 
1.4.3 Genotyping  
The reference method for HCV genotype determination is direct sequencing of the NS5B or 
E1 regions of HCV genome. In clinical practice, HCV genotype can be determined by various 
commercial kits (Trugene® 5`NCH CV Genotyping kit, Bayer Health care, INNO-LiPA HCV 
II, Innogenetics, Versant® HCV genotyping assay, Bayer Health care). Genotype tests are 
important clinically because they predict most accurately the chance of antiviral response, and 
dictate the duration of therapy. Genotype is the strongest predictor of response to interferon 
and ribavirin; patients who had genotype 2 or 3 were 3 to 6 times more likely to achieve 
sustained virological response (SVR) in the 2 large registration trials of peginterferon [31, 
32]. Therefore, genotyping is necessary before initiation of therapy.  
 
1.4.4 Diagnosis of acute HCV infection 
The presence of HCV RNA in the absence of anti-HCV antibodies is a strong indicator of 
acute HCV infection, which will be confirmed by seroconversion days to weeks later (fig 3). 
Acutely infected patients can also have both HCV RNA and anti-HCV antibodies at the time 
of diagnosis. It is difficult, in this case, to distinguish acute hepatitis C from an acute 
exacerbation of chronic hepatitis C. Acute hepatitis C is very unlikely if both anti-HCV 
antibodies and HCV RNA are absent or if anti-HCV antibodies are present without HCV 
RNA.  The presence of anti-HCV antibodies in the absence of HCV RNA is generally seen in 
patients who have recovered from past infection. 
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Figure 3: Use of Molecular Tests for Diagnosis of Acute Hepatitis C Virus Infection Following Known 
Exposure 
*Repeat HCV RNA testing at 16 to 24 weeks if the patient had previous negative qualitative test results.  
†Repeat anti-HCV antibody testing at 16 to 24 weeks if patient had a negative anti-HCV test result at 4 to 6 
weeks after exposure [30]. 
 
1.4.5 Diagnosis of persistent hepatitis C 
In patients with clinical or biological signs of chronic liver disease, chronic hepatitis C 
infection is certain when both anti-HCV antibodies and HCV RNA are present. Detectable 
HCV replication in absence of anti-HCV is exceptional but found in profoundly 
immunsuppressed patients and haemodialysis patients. 
 
1.5 Treatment 
1.5.1 Chronic hepatitis C virus infection 
Interferon, used as monotherapy for HCV infection for many years, gives a SVR in < 20% of 
patients. The introduction of combination therapy with interferon-α and oral ribavirin was a 
major success [33]. This regimen shows a SVR, as defined by undetectable virus RNA in the 
peripheral blood at 24 weeks after stopping therapy, in 40% of previously untreated patients 
with chronic HCV infection. More recently, combination therapy using interferons modified 
by the addition of either a 12-kDa or a 40-kDa polyethylene glycol molecule (peginterferons) 
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was found to be superior to combination therapy involving standard interferon or treatment 
with peginterferon alone [31, 32]., The combination of peginterferon and ribavirin given for 
48 weeks, which is the current best therapy for chronic hepatitis C, yields overall SVR rates 
of 50% to 60% [31, 32]. Importantly, response rates are higher among patients infected with 
genotypes 2 and 3 (75% to 80%) than with genotype 1 (46% to 52%) and can be achieved 
with 24 weeks of therapy and lower doses of ribavirin (800 mg rather than 1000-1200 mg 
daily) [34]. Analyses of HCV RNA levels during antiviral therapy have identified important 
factors associated with response. These factors include both viral (HCV genotype and initial 
HCV RNA level) and host factors such as age, sex, race, body weight, hepatic steatosis, 
insulin resistance, hepatic fibrosis, immunodeficiency, adherence, and presence of other 
comorbidities.  
 
1.5.2 Mechanisms of interferon  
The outcome of any viral infection depends on innate and adaptive immune responses. 
Immune reactions are first triggered by engagement of pathogen-associated molecular pattern 
(PAMP) receptors that sense the viral threat and induce an antiviral state through a myriad of 
pathways including activation of IFN. IFN-α/β acts to induce antiviral responses in cells via 
interaction with specific cell surface receptors, the type I IFN receptors. These in turn 
stimulate a number of pathways such as the phosphorylation of signal transducers and 
activators of transcription (STATs) which lead to gene expression [35]. These proteins are 
capable of disrupting viral gene expression at multiple levels, including viral mRNA stability, 
transcription and translation. In addition to its direct antiviral actions, IFN acts as an 
immunomodulator by promoting memory T-cell proliferation, preventing T-cell apoptosis, 
and stimulating NK cell activation and DC cell maturation [36, 37]. Exogenously supplied 
recombinant IFN-α binds to and activates cellular receptors, leading to the same response 
cascades that occur with endogenous production.  
 
1.5.3 Ribavirin: Mechanism of action in chronic hepatitis C 
Ribavirin was introduced into hepatitis C virus therapy in the early 1990s and monotherapy 
was associated with improvements in serum ALT levels in half of the patients but the viral 
level was persisting. The addition of ribavirin to IFN-α-based regimens produced dramatic 
improvement in SVR rates among patients with chronic hepatitis C. Ribavirin clinically 
appears both to increase the end-of-treatment response rate and to decrease the subsequent 
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relapse rate [36]. The mechanism by which this effect occurs has not been elucidated. Several 
hypotheses for the mechanism of action of ribavirin have been proposed (Figure 4): (1) a 
direct antiviral effect against the HCV RNA-dependent RNA polymerase; (2) depletion of 
intracellular guanosine triphosphate (GTP) pools through its action as an inhibitor of inosine 
monophosphate dehydrogenase (IMPDH); (3) induction of misincorporation of nucleotides by 
the viral RNA polymerase, leading to lethal mutagenesis and production of virus with 
diminished infectivity; and (4) enhancement of host T cell-mediated immunity against viral 
infection through switching the T cell phenotype from type 2 to type1. 
 
 
Figure 4: Ribavirin: proposed mechanisms of action. GMP guanosine monophosphate; GTP, guanosine 
triphosphate; IFN-, interferon; IMPDH, inosine monophosphate dehydrogenase; RDP, ribavirin diphosphate; 
RdRp, RNA-dependent RNA polymerase; RMP, ribavirin monophosphate; RTP, ribavirin triphosphate; Th1, T 
helper 1; and Th2, T helper 2 [37] 
 
Viral kinetic studies during IFN- therapy of chronic hepatitis C have defined two phases of 
viral decline: a rapid, initial first phase, which is believed to reflect antiviral efficacy of IFN-
α, and a more delayed and slower second phase, which is believed to reflect eradication of 
virus-infected hepatocytes. Using kinetic models, it has been proposed that ribavirin exerts its 
effect predominantly in the second phase of viral decay, through increased mutagenesis, 
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resulting in a lower rate of new productively infected hepatocytes [38]. These findings 
support a theoretical model wherein ribavirin, through its mutagenic actions, lowers HCV 
fitness. Ribavirin might reduce the ability of HCV to escape immune and antiviral pressures, 
and thereby increase the effectiveness of IFN by decreasing replicative fitness and narrowing 
the genomic diversity of HCV [37]. 
 
1.6 Rational for the study 
Interferons are known to modulate immune responses. Moreover the biologic effects of 
various lFN are quite heterogenous and IFN has been shown to inhibit cell growth, to activate 
natural killer cells and to affect leukocyte migration. From studies in mainly animal models it 
has also been demonstrated a modulating effect of IFN on B cell functions, particularly 
measured as immunoglobulin IgG production in vivo and in vitro [39-43]. The experimental 
data of these studies indicate that IFN induces enhanced production of immunoglobulins 
indirectly via effects on CD4+ T cells and dendritic antigen-presenting cells [42, 43]. More 
specifically, IFN enhances the primary antibody response, stimulates the production of all IgG 
subclasses and induces long-lived antibody production against the stimulating antigen. Multi 
model activities of IFN have made use of IFN in various medical conditions like 
malignancies, viral and immune-mediated diseases. Currently, IFN has shown clinical benefit 
in Multiple Sclerosis (MS) and in chronic hepatits C infection. Ulvestad et.al have shown that 
interferon induces a significant increase in total IgG and C1 inhibitor (INH) in patients with 
MS, thus verifying that interferon modulates and activates both innate and adaptive immune 
system in these patients [44]. A question is whether IFN also induces the production of Igs in 
a more unspecific manner, thereby enhancing the total concentration of serum Igs.  
 
 It has previously been shown that in chronic liver disease there is a marked increase in 
morbilli and/or rubella antibodies [45-47]. This finding was prominent in autoimmune chronic 
hepatitis (AICH) and the authors tried to explain this as a reactivation of these viruses and or a 
general hyper reactive B-lymphocyte system since reactivation without clinical laboratory 
verification of viruses may influence the total IgG. Therefore, the aim of the project was to 
see more specifically whether the increased IgG levels were primarily due to HCV antibodies 
or whether antibodies against other viruses such as adenovirus, morbilli virus, and rubella 
virus were also increased. 
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2. AIM OF THE STUDY 
The primary aim of this work was to study the effects of the combination therapy on the 
immunoglobulin levels. More specifically to see whether, the increased IgG levels were 
primarily due to HCV antibodies or whether antibodies to other viruses such as adenovirus, 
measles virus, and rubella virus are also increased. 
 The specific tasks were: 
  
- To analyse the variation in IgG by quantification of total IgG in chronic HCV patients 
during combination therapy. 
- To see whether antibody titers to other viruses like adenovirus, measles virus, and     
rubella virus are influenced by the increase in total IgG. 
- To quantitate total anti-HCV antibody titers in responders and non responders. 
- To establish an in-house Elisa assay for detection of anti-C22 antibodies. 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
NorDynamIC was a Randomized, Open-label, Parallel Group, Multi-centre Study of 12 weeks 
treatment and follow-up period of 36 weeks (Group1) versus 24 weeks treatment and follow-
up period of 24 weeks (Group2). The patients were untreated, and chronically infected with 
HCV genotype 2 or 3. The treatment consisted of Peginterferon alfa-2a 40kD (PEGASYS®) 
combined with Ribavirin (Copegus®) [48]. NorDynamic and the amendments for our study 
were clarified by RKK (Regional komite for med.forskningsetikk) and NSD 
(Personvernombudet for forskning).The sera were collected in the period from February 2004 
till March 2006. The samples were stored frozen at -70 o C. 
Our study included the 24 patients enrolled in the study at Haukeland University Hospital. 
These patients’ sera were collected at the following time points: day 0 (before start of 
treatment), day 3, 7, 8, 14, 29, and week 8, 12, 16, 20, 24, 36 and 48. See table-1. 
 
Table-1: Schedule of serum collection 
Study points 1 2 3 4 5 6 7 8 9 10 11 12 13 
day/week d0 d3 d7 d8 d14 d29 w8 w12 w16 w20 w24 w36 w48 
Group 1 x x x x x x x x na na x x x 
Group 2 x x x x x x x x x x x x x 
                                                          (na: not applicable to group 1) 
In addition there were some sera missing from the study points. These are shown as missing 
(m) in the respective tables. 
 
3.2 Methods 
3.2.1 Nephelometer 
Total IgG in all the sera was quantified by using nephelometer.  
The quantification in nephelometer is based upon the specific reaction of an anti-IgG specific 
antiserum with the human IgG to be determined. The generated immune complexes are 
quantified by measuring the side-scattered light. It is an automated assay with relatively short 
incubation time. The samples were diluted and standard and control sera were introduced in 
the reaction tubes of the nephelometer. Anti-IgG reagent and reaction buffer were then added 
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and side-scattered light was recorded. Total IgG concentration in the test samples were then 
calculated relative to the calibration curve, which was obtained with the IgG standard serum. 
A control serum was assayed to check the validity of the calibration curve. 
We have used kit from Dade Behring Inc. See table-2. 
 
Table-2:  Reagents and instruments in total IgG quantification 
    Instrument- Dade Behring BN II 
    Antiserum for human IgG - Rabbit anti-human IgG 
    Protein Standard SL (human) 
    Protein Control SL/M (human) 
    Reaction Buffer 
    Diluent Buffer 
    Distilled water with 25% Tween 
 
3.2.2 Complement Fixation Test (CFT) 
Complement fixation test was used to detect antibodies (IgG) against adeno virus and morbilli 
virus. The serum samples were diluted 1:4 with veronal buffer (VB) (see table-3). Diluted 
patient sera, positive and negative controls were incubated in a water bath at 56o C for 30 
minutes to inactivate endogenous complement. Antigens, run control antibodies, complement 
and VB were prepared according to the procedure from Serion Immunodiagnostica GmbH. 
Microtiter plates (96 wells, U bottom) were used for titration. A pre-programmed pipetting 
instrument (Micro Lab® AT Plus, Hamilton Company, USA) was used for titration. Titration 
started with addition of 25µl VB to each well. Then 25µl of 1:4 diluted serum was added to 
well number one and from there two-fold titrations were done up to well number seven which 
results in dilutions from 1:8 up to 1:512. In well number eight, 25µl of 1:4 diluted serum was 
added without serum antigens to serve as control for detection of anti-complementarity. 
Thereafter 25 µl of antigen dilution was added to wells 1-7 and 25 µl of VB was added to well 
number eight (serum control). Finally, 25 µl of complement solution was added and plates 
were incubated overnight at 2-8 o C.  
Indicator system was prepared by mixing amboceptor (haemolytic anti-sheep erythrocyte 
serum) and sheep erythrocytes. Packed sheep erythrocytes (Dade Behring) were washed by 
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centrifugation at 2000 rpm for 20 minutes twice in physiological salt water and three times in 
VB. Working solution of sheep erythrocytes (0.8%) was prepared by diluting in VB.  
Amboceptor working solution was prepared by diluting the stock solution to 1:100 with VB 
(350µl amboceptor diluted in 9, 4 ml VB and 300 µl 5% phenol). 
The haemolytic system was prepared by mixing amboceptor working dilution and erythrocyte 
suspension in equal parts and incubated at room temperature for a minimum of 30 minutes to 
allow the erythrocytes to be sensitized and kept at 2-8 Co overnight. 
The second day the plates with sera were incubated for 30 minutes at 37o C and 50 µl 
haemolytic system was added to each well and incubated for 30 minutes at 37o C. Then plates 
were incubated at 4-8 Cº for about 1 hour before reading. Total haemolysis was recorded as 
negative reaction and total inhibition of haemolysis recorded as positive reaction and the 
highest titer recorded as result. See table-3, for materials used in CFT. .The explanation for 
recording the results from CFT is shown in appendix-1 
 
Table-3: Reagents and instruments used in CFT 
Instrument for titration: Micro Lab® AT Plus, Hamilton Company. 
Reagents from Serion Immunodiagnostica GmbH 
Antigens: Lyophilized adeno virus and measles virus antigens isolated from infected cells. 
Positive/Negative control sera: Lyophilized adeno virus and morbilli virus human control sera. 
Complement: Lyophilized pig serum. 
Veronal Buffer: Dissolve vial in distilled water, pH 7,3 +/- 0,1 
Haemolytic system from Dade Behring Inc. 
Amboceptor: Haemolytic anti-sheep serum. 
Erythrocytes: Packed sheep erythrocytes in solution. 
Other Reagents 
Physiological salt water: To wash packed sheep erythrocytes, pH 7,3 +/- 0,1 
 
3.2.3 Microparticle Enzyme Immunoassay  
Abbott semiautomatic Axsym system was used for Rubella IgG antibody detection. The 
Axsym system is a microparticle enzyme immunoassay (MEIA) for the qualitative and 
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quantitative detection of IgG antibodies. Diluted serum samples and microparticles coated 
with partially purified rubella virus (strain HPV77) antigen were mixed and incubated in the 
processing centre according to the manufacturer’s instructions. Microparticles coated with 
rubella virus antigen would then bind to rubella antibodies forming an antigen-antibody 
complex. 
An aliquot of the antigen-antibody complex was transferred to the glass fibre matrix where 
microparticles bound irreversibly to the matrix. Unbound materials were then removed by 
washing. An alkaline phosphatase conjugated anti-human IgG was dispensed onto the matrix 
cell and then bound to the antigen-antibody complex. Unbound materials were removed by 
washing the matrix cell. Then 4-Methylumbeliferyl phosphate (MUP) substrate was added to 
the matrix cell and emitted fluorescence was measured in the Axsym instrument. Results are 
given in IU/ml which is calculated from the master calibration curve. See table-4, for Rubella 
IgG quantification in Abbott Axsym system. 
 
Table-4: Reagents and instruments in quantification of rubella IgG 
Instrument: Abbott Axsym System® 
Reagents for Rubella IgG 
Antigen: Partially purified Rubella Virus (strain HPV77) coated on microparticles 
Conjugate: Goat anti-Human IgG conjugated with alkaline phosphatase 
Assay Diluents: For serum dilution 
Run Controls  
Negative: Non reactive pooled human serum for anti-rubella IgG  
Positive: Reactive pooled human sera to anti-rubella IgG 
Substrate:  4-Methylumbeliferyl phosphate (MUP) 
Matrix cell wash: 0,3M Sodium Chloride  
 
Both positive and negative controls are non reactive to anti-HIV1/2, HIV-1Ag, HBsAg, and to 
anti-HCV.  
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3.2.4 Chemiluminiscence Microparticle Immuno Assay  
The ARCHITECT Anti-HCV assay from Abbott Laboratories is  a two-step immunoassay 
using the Chemiluminescence microparticle immuno assay (CMIA) technology with 
recombinant HCV antigen-coated paramagnetic microparticles and murine anti-IgG/anti-IgM 
acridinium-labeled conjugate. All sera were tested in 1:50 dilution. Testing was done 
according to the manufacturer’s instructions. Briefly, the diluted serum samples, recombinant 
HCV antigen coated paramagnetic microparticles and assay diluent were mixed. Anti-HCV 
antibodies present in the samples would then bind to HCV coated microparticles. After 
washing, anti-human acridinium-labeled conjugate was added. Pre-Trigger and Trigger 
solutions were added after another wash cycle. The resulting chemiluminescent reaction was 
measured as relative light units (RLUs) by the ARCHITECT optic system. Results were 
calculated automatically and presented as sample/cut off (S/CO). See table-5, for reagents and 
instrument to detect anti-HCV. 
 
Table-5: Reagents and instruments in detection of anti-HCV 
Instrument : Abbott Architect System® 
Reagents for anti-HCV 
Antigen: Recombinant HCV antigen coated on paramagnetic microparticles. 
Conjugate: Acridinium labelled Murine anti-Human IgG/anti-IgM conjugate. 
Assay Diluents: For serum dilution 
Run Controls  
Negative: Non reactive pooled human serum for anti-HCV  
Positive: Reactive pooled human sera to anti-HCV 
Pre-Trigger: 1,32% (w/v) hydrogen peroxide solution 
Trigger: 0,35 N Sodium hydroxide 
Wash buffer: Phosphate buffered saline solution 
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3.2.5 ELISA 
An in-house anti-HCV EIA was designed to detect anti-HCV core IgG using recombinant 
C22 core antigen from Feldan Bio Inc (Quebec, Canada). In brief, the wells of microtiter 
plates (Maxi Sorp, Nunc) were coated with different concentrations of antigen in 100 µl 
antigen coating buffer. The plates were then incubated overnight at 4oC or at room 
temperature. The coating buffer was removed and 200 µl of different blocking buffers were 
added. All the blocking buffers (except Super-Block) were incubated for 2 hours at 37oC in a 
humid chamber. Then the plates were washed 3 times using PBS with 0, 05% Tween 20. For 
Super-Block, the buffer was removed immediately after addition by inversion of the plate and 
this procedure was repeated three times. The plates were then packed in plastic bags and 
stored at 4oC.  For the ELISA assay, 100 µl patient sera in different dilutions (1:50, 1:100, 
1:500, 1:1000, 1:10000) were added to the wells and incubated for one hour at 37oC. After 
three washes with PBS with 0, 05% Tween 20, 100 µl conjugate of different types was added 
in different dilutions (1:25, 1:50, and 1:100) and the plates were incubated for 30 minutes at 
37 o C. Plates were then washed four times. Finally, 100 µl of the appropriate substrate was 
added according to the enzyme conjugate, and incubated at 18-25oC for 30 minutes. The 
reaction was stopped by adding 100 µl 0, 5 N sulphuric acid and absorbance was read in a 
micro-titer plate reader at a wavelength of 450nm. See table-6 for details of reagents and 
instruments used for in-house Elisa. 
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Table-6: Reagents and instruments for in-house Elisa assay 
Instruments 
Microplate washer: Athos company 
Microplate Reader: Athos company 
Data Program Microplate Reader: Megallan company 
Antigen 
Recombinant Hepatitis C Virus Core - rHCV 
Catalogue # Clone Concentration Purity Supplier 
FB01-80-1203 rHCV 1 mg/ml  >95% Feldan Bio Inc, Canada. 
Blocking Buffer 
Non-fat Dried Milk: Gene Labs Diagnostics (From the HIV 1/2 Western Blot Kit), Singapore. 
Foetal Bovine Serum: PAA Laboratories GmbH, Austria. 
Super Block Blocking Buffer in PBS: Pierce Biotechnology, USA. 
Conjugates 
Rabbit anti-human IgG HRP: Parvo IgG Elisa kit, Biotrin International Ltd, Ireland. 
Goat anti-human IgG HRP: EBV VCA IgG Elisa kit, Novitec, HISS Diagnostics GmbH, Germany 
F(ab) Rabbit anti-human IgG HRP: Enzygnost® VZV IgG kit, Dade Behring 
Substrates  
Tetramethylbenzidene (TMB)  
Stop solution 
1) 0, 5 mol/l Sulphuric acid from Parvo kit. 
2) 0, 5 N Hydrochloric acid from EBV kit or the Enzygnost® kit. 
Coating Buffer 
15 nM Na2CO3, 35 mM NaHCO3 and 3 mM NaN3 at pH 9,6 
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4. RESULTS  
 
4.1 Total IgG Quantification 
Total IgG was analysed in serum at the different time points and data are presented in tables-
7a and -7b in appendix-2.  
Graphically data from all sera are illustrated in figure 5a (see below). Data points from weeks 
16 and 20 are excluded because not all patients were included at those dates. It can be seen 
that there is a marked increase in IgG levels from day 0 to day 8, and a sharp drop till week 8. 
Most of the sera had the lowest levels of total IgG at week 8 and mean IgG value almost 1g/l 
lower than at start of the therapy. From week 8, total IgG levels increase and return to 
baseline. During the first 24 weeks, values for total IgG at day 0 and week 24 were similar 
whereas day 8 has the highest values and week 8, the lowest values. These time points (d 0, d 
8, w 8 and w 24) give clear differences in the IgG levels and were selected to explore the 
antibody patterns to other viruses such as adeno virus, morbilli virus and rubella virus. 
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Figure 5a: Mean total IgG over 24 weeks for all patients 
 
Of the 24 patients in the study, 19 were responders and 5 were non-responders. Interestingly, 
it turned out to be that all the non-responders were in the 12 week therapy group. Figure 5b 
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shows the total IgG curves of mean values for responders and non-responders. In responders 
mean total IgG values continue to decline after the cessation of therapy at week 24. However 
in non-responders there is an increase of total IgG level from week 24 to 36 and it falls back 
to level lower than baseline at week 48. Figure 5b further clearly shows that the mean total 
IgG level at each time point studied is higher in non-responders than in responders. 
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Figure 5b: Mean total IgG for responders and non-responders 
 
4.2 Anti-rubella antibody levels and relationship with total IgG 
All patients were anti-rubella IgG positive (> 8 IU/ml) at baseline see table-8 (Appendix-3). 
Anti-rubella IgG levels varied considerably and showed 100 fold difference in range. To see 
whether the changes in the total IgG were reflected in changes in anti-rubella titers, the data 
were analysed separately for each patient and are presented in Figure 6a (Appendix-4). 
 Thirteen sera (3803, 3804, 3805, 3809, 3811, 3814, 3815, 3816, 3817, 3819, 3820, 3824, and 
3825) showed the same patterns for rubella IgG and total IgG. Eight sera (3806, 3808, 3810, 
3812, 3813, 3818, 3822, and 3826) tended to show the opposite pattern and three sera (3807, 
3812, and 3823) had no clear pattern. Figure 6b gives an illustration of these patterns.  
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Figure 6b: Patterns of reactivity between rubella IgG and total IgG 
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4.2.1 Rubella IgG and total IgG in responders and non-responders 
Figure 6c shows the pattern for rubella and corresponding total IgG in responders and non- 
responders. Even though the patterns differ between the two groups with respect to IgG levels 
after week 8, there was a relationship between rubella IgG and total IgG. The curves are more 
or less parallel. 
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Figure 6c: Rubella IgG and total IgG in responders and non-responders 
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4.3 Reactivity to adeno virus and morbilli virus and relationships to total IgG and 
rubella antibodies 
The results from CFT to adeno virus, morbilli virus and corresponding total IgG values are 
shown in table-9a (Appendix-5). It can be seen that, there are fewer patients with antibodies to 
adeno virus than to morbilli virus. For some of the patients a two fold increase in titer can be 
seen during therapy, which is not significant. There is thus no evidence that adeno virus and 
morbilli virus antibodies have influence on the total IgG levels. 
In order to analyse the results of adeno virus and morbilli virus and comparing these with 
rubella virus and total IgG, the data was sorted according to the reactivity in the CFT. See 
table-9b. (Appendix-6) 
 
4.3.1 No antibody reactivity to adeno virus and morbilli virus 
Sera with no reactivity to adeno virus and morbilli virus combined with rubella and total IgG 
are shown in figure 7a (Appendix-7). Two sera (3811, 3822) have more or less the same 
patterns to total IgG and to rubella virus IgG whereas the other three (3808, 3818, 3826) had 
opposite curve patterns. 
 
4.3.2 No antibody reactivity to morbilli virus 
The sera which did not show any antibody reactivity or insignificant titers to morbilli virus 
showed also low or insignificant reactivity to adeno virus (figure 7b, Appendix-8). One 
exception is patient 3816 that had detectable anti-adeno antibodies and a slight but not 
significant increase between week 8 and week 24. Several sera (3803, 3807, 3809, 3814, 38 
16, 38 17 and 3825) showed the same pattern for rubella antibodies and total IgG but there 
was no relationship observed between adeno virus antibodies and total IgG in this group. 
 
4.3.3 No antibody reactivity to adeno virus 
The sera that did not show any or insignificant antibody titers to adeno virus, showed various 
reactivity to morbilli virus. See figure 7c (Appendix-9). Sera 3804, 3819, 3821, 3823 and 
3824 show a similar pattern for total IgG and rubella virus antibody. However there was no 
relation between morbilli virus antibodies and total IgG observed in this group either. The 
results showed that when there is high reactivity (>1:128) to morbilli virus, there is a tendency 
to get high amount of total IgG, especially in sera 3820 and 3824. Moreover in these two 
cases, there is also a very high reactivity to rubella virus. However, sera 3803, 3814, and 3815 
showed relatively high total IgG without any or little antibody reactivity to morbilli virus.  
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4.4 Anti-HCV titers and its relationship to total IgG 
4.4.1 Anti-HCV 
Table-10 (Appendix-10) shows the individual values for antibodies to HCV for all patients 
whereas figure 8a illustrates curves with mean values for responders and non-responders. In 
responders the antibodies to HCV declined continuously even after cessation of the treatment. 
Mean anti-HCV levels dropped from a value of 9 day 0 to 4,5 at week 48.  
It so happened that all five non-responders were in group 1, that had only 12 weeks of 
treatment and antibodies to HCV declined to week 12 but increased after treatment was 
stopped. Thus, once the treatment is stopped, levels of antibodies increased and returned to 
levels before treatment, indicating only a temporary response to treatment. 
 
4.4.2 Relationship between anti-HCV and total IgG 
The relationship between total IgG and antibodies to HCV for individual patients are shown 
in figure 8b (responders) and 8c (non-responders) (Appendix-11 and 12). In general shapes of 
the total IgG and anti-HCV curves follow each other quite well, both in responders and non-
responders. For some of the patients the two curves run in parallel whereas for others there is 
more variation. To get a better appreciation of the profiles, figure 8d was made to show mean 
values for total IgG and corresponding mean values for antibodies to HCV in responders and 
non-responders.  
For responders both curves are more or less parallel up to week 8. From week 8 to 24 there is 
an increase in total IgG whereas anti-HCV declines continuously. After 24 weeks both curves 
become parallel again.  
Interestingly the curves for antibodies to HCV and total IgG show remarkably similar profiles 
for the non-responders.  HCV antibodies and total IgG increased up to day 8 of treatment, and 
then levels were declining to week 12 for anti-HCV whereas total IgG had a fluctuation 
between day 29 and week 24. After cessation of therapy at week 12 the anti-HCV level 
increased above the baseline level. Total IgG showed a transient and delayed increase from 
week 24 to 36 and thereafter declined below the baseline level at week 48.  
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Figure 8a: Mean antibody levels to HCV in responders and non-responders 
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Figure 8d: Mean values of antibodies to HCV and total IgG in responders and non-responders 
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4.5 In-house ELISA 
Several different combinations of conjugates and blocking buffers were used to establish the 
in-house Elisa with the commercially available antigen. Table-11 summarizes the different 
combinations used in the efforts to establish the test. All in all, sera from five HCV positive 
patients with high and four patients with low anti-HCV antibody levels were included. 
Negative control sera were obtained from six blood donors.  
 
Table-11: Different combinations used to establish in-house ELISA.  
Plate nr 
Antigen 
(ng/well) Conjugate  Blocking Buffer  
1 100, 200 
F(ab) Rabbit anti-human IgG 
Enzygnost® VZV IgG kit, Dade Behring 5 % Nonfat dried milk 
2 100 
F(ab) Rabbit anti-human IgG 
Enzygnost® VZV IgG kit, Dade Behring 20 % FBS 
3 50 
F(ab) Rabbit anti-human IgG 
Enzygnost® VZV IgG kit, Dade Behring 5 % Nonfat dried milk 
4 100 
Rabbit anti-human IgG HRP 
Parvo IgG Elisa kit, Biotrin International Ltd 5 % Nonfat driedmilk 
5 50 
Goat anti-human IgG HRP 
EBV IgG Elisa kit, Novitec, HISS Diagnostics 20 % FBS  
6 100 
F(ab) Rabbit anti-human IgG 
Enzygnost® VZV IgG kit, Dade Behring Super Block 
7 50 
F(ab) Rabbit anti-human IgG 
Enzygnost® VZV IgG kit, Dade Behring Super Block 
 
Plate 1 
OD values from Plate 1 are shown in table-12a (Appendix-13). Half of the plate was coated 
with 100 ng antigen per well and the other half coated with 200 ng. Only one dilution (1: 50) 
of conjugate was used. Four low positive anti-HCV sera (columns1-4 and 7-10) and one high 
positive serum (columns 5 and 11) were used. PBS was used as blank in the first four wells of 
the columns 6 and 12 and the remaining wells were used for undiluted negative sera from two 
blood donors in duplicate. Nonfat dried milk (5%) in PBS was used as blocking buffer. 
As seen from the table, there is no difference in OD values between sera with high or low 
anti-HCV antibody levels. Also, the anti-HCV negative sera show the same reactivity as the 
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positive sera. The use of higher or lower antigen concentration made no difference in OD 
values. 
 
Plate 2 
One antigen concentration (100 ng/well) and two conjugate concentrations (1:25, 1:50) were 
used. Three high positive (columns 1-3 and 7-9) and two negative sera were used (columns 4-
5 and 10- 11). PBS was used as blank in the first four wells of columns 6 and 12 and the 
remaining four wells were used for undiluted negative sera. All sera were tested in duplicate. 
Wells were blocked by 20% FBS in PBS. 
OD values are shown in table-12b (Appendix-13). Highest OD values can be seen for 
undiluted negative control sera whereas there is no difference in OD values between diluted 
positive sera. Since the PBS blanks have very low OD values, this indicates non-specific 
binding throughout the plate in presence of human serum. OD values from wells with 1:25 
conjugate dilution is approximately twice as high as those with 1:50 dilution. 
There is no difference or improvement in using the FBS as blocking buffer. 
 
Plate 3 
The design for plate 3 is the same as for plate 2 but here the wells were coated with 50 ng 
antigen, and 5% nonfat dried milk was used for blocking. 
Similarly to plate 2, OD values are higher with higher conjugate concentration. Again, it was 
not possible to distinguish between the positive and negative sera though blocking was done 
with 5% nonfat dried milk. See table-12c (Appendix-13). 
 
Plate 4  
In plate 4, a new conjugate was tested undiluted (ready to use from the Parvo-kit) and diluted 
1:2. The plate was coated with 100 ng antigen per well and blocked by 5% nonfat dried milk. 
Even though OD values were almost doubled with high concentration of conjugate, it does not 
differentiate between positive and negative sera. Background is high except for blanks. 
This shows that different conjugate does not solve the problem with the high background. See 
table-12d (Appendix-13) 
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Plate 5 
Plate 5 was coated with 50 ng antigen per well. Another new conjugate from the EBV-kit was 
used undiluted (ready to use) and diluted1:2. The other parameters were the same as for plate 
4. Again, the OD values were very high and gave no difference with the two concentrations of 
conjugates used, and do not differentiate between positive and negative serum. Blanks had 
very low OD values and were comparable to the other plates. See table-12e (Appendix-13).  
 
Plate 6 
At this point, the commercial antigen supplier (Feldan Bio Inc, Canada) was contacted in 
order to discuss the problem. However, the supplier could only give the information that the 
product was used for ELISA tests by three large diagnostic companies, and by four others 
used in rapid diagnostic kits. Due to confidentiality agreements between the companies, 
Feldan Bio Inc could not disclose any procedures or customer references, but they suggested 
lowering the antigen concentration to 100 ng, which was already tried in different 
combinations (Plates 1, 2 and 4).The choice was to use a new blocking buffer (Super Block) 
since nonfat dried milk and FBS could not discriminate positive sera from negative in the 
previous tests. 
Plate 6 was coated with100 ng antigen/well and two dilutions of the conjugate (1:50 and 
1:100) were used. Five positive (wells A1 to G3) and five negative sera (wells A3 to G4) were 
used in three dilutions (1:50, 1:100 and 1:1000) and added to 4 single wells as shown in table-
12f (Appendix-13). A high positive serum in two-fold dilutions (starting from dilution 1:50 to 
1:6400) was added in column 5. A negative serum titrated in two fold (1:50 – 1:200) in first 
four wells in column 6 and the remaining wells were used for PBS as blanks. The same setup 
applied for the other half of the plate with a different conjugate concentration.  
Table-12f (Appendix-13), shows that the OD values are lower with Super Block as compared 
to the other blocking buffers. Still there is no discrimination between the positive and the 
negative sera. PBS blanks continue to show very low OD values. Thus, with the use of Super 
Block, the OD values are considerably lower. Higher or lower concentrations of the conjugate 
also did not make any difference. 
 
Plate 7 
The wells were coated with 50 ng and all other conditions were the same for plate 6 (Table-
12f). OD values for plate 7, shown in table-12g (Appendix-13) were very low. Thus lowering 
the antigen concentration shows no improvement in OD values compared to plate 6. 
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5. DISCUSSION 
 
Current guidelines for chronic Hepatitis C recommend peginterferon-alpha and ribavirin 
combination therapy for 24 or 48 weeks, based on viral factors (genotype, viral load), host 
factors (stage of liver disease) and virological response during treatment. The main goal of the 
treatment is eradication of HCV infection which is defined by HCV RNA negativity 24 weeks 
after end of treatment (i.e. sustained virological response). It has long been recognized that 
patients with HCV genotype 2 or 3 respond better to IFN treatment than patients infected with 
HCV genotype 1 [49]. Roughly 80% of patients with HCV genotype 2/3 are cured from their 
disease after the combination treatment.  
 
Although immune mediated mechanisms are likely to be involved in the pathophysiology of 
chronic HCV-infection little is known about the effects of interferon on immunoglobulin 
synthesis in these patients and in particular in combination with Ribavirin. This study was 
conducted in order to study the effects of the combination therapy on the total 
immunoglobulin levels in HCV patients. 
 
The sera included in this study are from the 24 patients included in the NorDynamIC study at 
Haukeland University Hospital. The patents had confirmed chronic HCV hepatitis with 
compensated chronic liver disease and were infected with genotype 2 or 3 and had no history 
of other immunomodulating treatment. Approximately 80 % (19 patients) showed good 
response to the combination therapy that is in line with previous findings [49]. All five non-
responders were in group 1 with treatment for 12 weeks whereas only 4 patients in the 
responding group had 12 weeks of treatment. 
 
The main aim of this work was to study whether the combination therapy with IFN and 
ribavirin would affect total IgG in chronic HCV patients like it has been found for IFN-
treatment for MS patients [44]. Interestingly the results showed that total IgG is increased 
already three days after start of therapy for most of the patients. The increase continued up to 
day eight. After that the mean total IgG curves showed a clear decline with a minimum value 
at week 8, almost 1 g/l lower than the level at the start of therapy. There is thus an early and 
clear effect on total IgG levels by the combination therapy in patients with chronic HCV 
infection. This was not observed for the MS patients, possibly because the earliest observation 
was at three months of therapy. However the variation in the IgG levels during treatment and 
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a clear decline to levels even below the pretreatment total IgG levels differed from the 
elevated total IgG values during IFN treatment in MS patients which lasted even six months 
after termination of treatment [44].  
 
Also in contrast to findings for the MS patients total IgG decline to levels even below those 
for pretreatment in the HCV patients [44]. The same finding was observed even for the five 
non-responders. It has been shown previously that in chronic HCV infections there is an 
increase in total IgG and some subclasses (IgG1, IgG2, and IgM) but no difference in IgG 
level when the extent of liver disease was considered [50-52]. However, Ulvestad et al 
showed in their study that there was elevated IgG even after the termination of IFN treatment 
[44]. Although IFN-α and -β are best known for their role in promoting innate anti-viral 
immunity, numerous studies have recently indicated a more pervasive role for these cytokines 
in the adaptive immune response. Emphasis has also been put on the capability of type I IFNs 
to connect and integrate the functioning of the innate and adaptive immune systems [43]. 
 
The anti-HCV antibodies showed a gradual decline in the responding group, whereas total 
IgG showed variation during the treatment period up to 24 weeks. The underlying mechanism 
is not known but can be speculated to be due to the variation in activation of immunogobulins 
by immunomodulating treatment. Tamura et el, showed that total anti-HCV core (anti-HCc) 
IgG titre correlated well with the IgG1 titre, indicating that IgG1 was the main virus-specific 
IgG and the changes of IgG1 production mainly contributed to fluctuations of the anti-HCc 
IgG titre and was related to positivity for HCV-RNA during and after IFN therapy. To our 
knowledge, there is no other study which shows the relationship between total IgG and anti 
HCV during combination therapy and the possible reasons for the elevated total IgGs. 
Furthermore, the analysis of non-responders revealed that total IgG decreased while patients 
were on therapy and tended to increase after the cessation of therapy. Interestingly for the 
non-responders there was a correspondence between antibodies to HCV and total IgG. The 
increase in total IgG after the termination of therapy is difficult to explain only by IFN 
therapy. The possible explanation for this may be the persistent activity of HCV that result in 
antibody synthesis which may contribute to the increase in the total IgG level. This issue has 
to be studied further. 
 
In this material reactivity to either adeno virus or morbilli virus was not found for the majority 
of sera. Moreover, there was no correspondence between antibody levels for morbilli or adeno 
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viruses and total IgG. This is in contrast to previous studies where it has been shown that in 
chronic liver disease there is a marked increase in morbilli and / or rubella virus antibody 
titers [45-47]. In the present study our results indicate that there was no increase in antibodies 
to either adeno or morbilli viruses which could have influenced the total IgG levels in chronic 
HCV patients. 
  
Interestingly, all the sera in this study showed good antibody reactivity to rubella virus which 
may indicate a non-specific effect or production of rubella antibodies due to 
immunomodulatory effect of IFN therapy. The results further show that there is a 
correspondence between the mean rubella antibody levels and mean IgG levels both in 
responders and non-responders, which may indicate that the total IgG level may be influenced 
by the rubella antibodies. Several studies have previously shown an increase in rubella 
antibodies in chronic liver disease but the exact mechanisms for this finding have yet to be 
clarified [45-47, 53]. Similarly, further studies are needed to clarify the issue of the 
production of rubella antibodies due to IFN therapy in chronic HCV patients.  
 
One of the aims of the study was to establish an in-house Elisa for detection of anti-C22 
antibodies to see whether the level of antibody has any relationship to total IgG, anti-HCV 
and to viremia in responders and non-responders. We have tried different combinations of 
conjugates, conjugate dilutions, different concentrations of antigen per well, different 
dilutions of sera and different types of blocking buffers. Every attempt of the different 
combinations did not give satisfactory results. We were informed by the antigen supplier that 
three big diagnostic companies were using the particular antigen in Elisa methods and four 
others were used in rapid test. We could not find any references either from Medline search or 
from the supplier because of the confidentiality agreement with the customers. Our attemps in 
establishing an Elisa method have so far failed and we could not find any specific reasons for 
this. A possible explanation can be related to the antigen. Recently, we have found out that the 
antigen supplier have changed the catalogue number of the product and thus possibly the 
characteristics of the antigen.  
The study concludes that there seems to be an effect of combination therapy on total IgG and 
total IgG levels corresponds well with the anti-HCV antibody levels in responders. Rubella 
antibody was increased in all chronic HCV patients in the study and seems to have 
relationship with the total IgG level. Antibodies to adeno and morbilli viruses were not 
influenced by the treatment. 
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APPENDIX-1 
 
 
  
P1 
 
P2 
 
P3 
 
P4 
 
P5 
 
P6 
 
P7 
 
P8 
 
P9 
+ 
cont 
- 
cont 
Serum 
control 
           
>512            
1:256            
1:128            
1:64            
1:32            
1:16            
1:8            
Titer <8 1:8 1:16 1:32 1:64 1:128 1:256 >512 AC 1:64 <8 
 
Explanation for recording of results of CFT. P1- P9; Patient number, AC – Anti 
complementarity.  Antigen and sera mixed together in the presence of complement. Any 
complex formed will fix the complement remaining in the system. Addition of haemolytic 
indicator system (sheep erythrocytes coated with antibodies) demonstrates the presence or 
absence of a specific reaction: when added to a system containing complement, this indicator 
system will be attacked by the, activated complement and the erythrocytes lysed. If the 
complement has been used up by antigen-antibody complexes in the serum, the erythrocytes 
will stay intact. After incubation a “button” of erythrocytes show the positivity of CFT. P1 
shows total lysis of erythroctes and results was read as negative or titer <8. From P2 to P8 
titers were read as 1:8, 1:16, 1:32, 1:64, 1:128, 1:256 and >512. Anticomplementary (AC) 
activity may result in false positive results. To identify AC serum control (test run without 
antigen) is included for each serum. P9 has a titer of 1:64 but shows anticomplementarity and 
has to be retested by pretreating the serum with undiluted complement. Positive and negative 
controls are also shown in the figure.  
 
APPENDIX – 2 
 
Table-7a: Total IgG in responders 
Pt. id D 1 D  3 D  7 D  8 D 14 D 29 W  8 W 12 W 16 W 20 W  24 W  36 W  48 
3803 16,7 18,9 20,3 18,9 18,1 15,6 16,5 15,9 16,2 14,8 16,9 14,9 m  
3805 12,7 16,2 15,5 16,5 15,2 16,4 13,9 14 11,6 14,8 14,6 12,9 12,2 
3806 13,4 14 13,9 13,6 14,4 14,1 12,6 13,1  na na  12,6        m 11,3 
3807 14,3 15,2 16,5 15,6 15,5 16,8 15,3 18  na na  15,8 15,3 16,3 
3808 12,5 15,3 13,5 13,7 12,9 14,7 12,4 14,5  na  na 13,5 11,6 12,7 
3809 11,7 12,3 11,9 12 12,1 11,1 11,1 11 11,4 11,9 13,1 11,1 10,3 
3811 7,8 8,51 7,56 7,83 8,9 8,07 6,06 6,39 6,11 5,37 6,39 7,82 6,68 
3812 12 11,2 12,4 12,2 11 9,69 9,95 9,69 10,6 10,9 11,4 11,5 9,59 
3813 11,4 12,2 11,5 11,4 11 11,3 11,3 11  na na  13 10,9 10,5 
3814 17,3 16,9 18,4 18,5 19,3 17,5 16,4 16,4  na na  16,1 13,3 10,6 
3815 16,5 16,6 16,2 17,8 18 17,2 16,9 18,2 19 17,6 20,1 16,3 13,2 
3816 13,7 14,2 14,8 14,1 13,9 11,8 10,1 10,9  na  na 13,1 m  12,3 
3817 9,79 12,6 12,8 13,9 12,9 11,1 10 11,2  na  na 12,7 11,6 10,8 
3818 10,6 11,4 11,9 11,6 11,3 12,2 11,6 11,4 11,6 12 10,8 10,8 9,86 
3819 11,7 11,4 11,9 12,2 11,8 10,9 11 11,2  na na  13 10,5 13,7 
3822 14,1 15,2 15,3 15 14,1 14,3 12,3 12,7 11,9 12,8 13,4 m  12,2 
3823 10,7 11,3 10,7 11,3 10,8 11,6 10,9 11,3 12,2 12,9 14 10,8 8,93 
3825 12,4 10,7 9,13 11,1 12,3 7,25 7,16 9,82 na  na  10,6 8,33 m  
3826 16,1 13,6 14,9 15,6 14,9  m 15,1 12,7 na  na 13  m m  
Mean 12,92 13,56 13,64 13,83 13,60 12,87 12,14 12,60 12,29 12,56 13,37 11,84 11,32 
 
Table-7b: Total IgG for non-responders 
Pt.id D 0 D 3 D 7 D 8 D 14 D 29 W 8  W 12 W 24 W 36 W 48 
3804 14,2 14 14,1 15,7 14,1 14,4 12,7 12,9 12 13 14,2 
3810 11,9 11,2 11 10,9 10,5 9,16 10,3 11,3 11,8 12 9,13 
3820 16,9 17,7 17,6 17,4 18,2 16,6 18 15,4 17,3  m 17,7 
3821 14,9 14,9 15,6  m 16,1 16,1 15,9 16,2 14,4  m m  
3824 19,7 22,1 21,2 20,7 18,1 15,7 16,8 15,2 14,9 20,9  m 
Mean 15,52 15,98 15,9 16,18 15,4 14,39 14,74 14,2 14,08 15,3 13,68 
    na - not applicable  m - missing serum 
APPENDIX - 3 
 
Table-8: Rubella IgG (IU/ml) and total IgG (g/l) for day 0, 8 and week 8 and 24. 
 
RUBELLA IgG - IU/ml 
 
Total IgG - g/l 
Pt.id   Day 0 Day 8 Week 8 Week 24 
 
Pt.id   Day 0 Day 8 Week 8 Week 24 
3803 63,7 111,6 56,4 109,9 
 
3803 16,7 18,9 16,5 16,9 
3804 518,6 635,6 576,9 706,4 
 
3804 14,2 15,7 12,7 12 
3805 224,9 256,5 193 947,7 
 
3805 12,7 16,5 13,9 14,6 
3806 215,5 157,4 229,6 165,4 
 
3806 13,4 13,6 12,6 12,6 
3807 67,6 54,1 62,1 88 
 
3807 14,3 15,6 15,3 15,8 
3808 260,5 220,7 281,9 206,9 
 
3808 12,5 13,7 12,4 13,5 
3809 68,8 72,9 56,8 124,8 
 
3809 11,7 12 11,1 13,1 
3810 120,8 137,5 150,3 140,3 
 
3810 11,9 10,9 10,3 11,8 
3811 32,3 29,6 28,3 31,6 
 
3811 7,8 7,83 6,06 6,39 
3812 388,7 289,4 377,2 454,9 
 
3812 12 12,2 9,95 11,4 
3813 269,6 334 374,4 309,1 
 
3813 11,4 11,4 11,3 13 
3814 229,2 254,1 203,6 115,2 
 
3814 17,3 18,5 16,4 16,1 
3815 80,3 170,5 128,5 318,7 
 
3815 16,5 17,8 16,9 20,1 
3816 101,2 100,4 61 123,7 
 
3816 13,7 14,1 10,1 13,1 
3817 168,6 161,9 106,7 471,3 
 
3817 9,79 13,9 10 12,7 
3818 254,4 211,6 217,7 284,3 
 
3818 10,6 11,6 11,6 10,8 
3819 136,3 140,3 121,5 156,3 
 
3819 11,7 12,2 11 13 
3820 1142,8 1167,9 1162,1 1199,1 
 
3820 16,9 17,4 18 17,3 
3821 357,8 m  466,8 350,1 
 
3821 14,9  m 15,9 14,4 
3822 39,7 34,9 36,9 204,6 
 
3822 14,1 15 12,3 13,4 
3823 47,2 53,2 51,1 45,7 
 
3823 10,7 11,3 10,9 14 
3824 2286,2 2578,7 1977,7 1663,2 
 
3824 19,7 20,7 16,8 14,9 
3825 791,1 721 655,5 1092 
 
3825 12,4 11,1 7,16 10,6 
3826 209,9 945,9 1166,1 1196,2 
  
3826 16,1 15,6 15,1 13 
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Figure 6a: Rubella IgG and Total IgG for day 0, day 8, week 8, and week 24 
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Table-9a: CFT results for adeno virus and morbilli virus and total IgG 
 
Day/week d 0 d 3 d 7 d 8 d 14 d 29 w 8 w 12 w 16 w 20 w 24 w 36 w 48
Pt. id.3803
Adeno 1:32 1:16 1:16 1:16 1:16 1:16 1:16 1:8 1:8 1:8 1:8 1:8 m
Morbilli < 8 < 8 < 8 < 8 < 8 < 8 < 8 < 8 < 8 < 8 < 8 < 8 m
IgG 16,7 18,9 20,3 18,9 18,1 15,6 16,5 15,9 16,2 14,8 16,9 14,9 m
Pt. id.3804
Adeno < 8 < 8 < 8 < 8 < 8 < 8 < 8 < 8 na na < 8 < 8 < 8
Morbilli 1:128 1:128 1.128 1:128 1:128 1:128 1:128 1:256 na na 1:256 1:256 1:256
IgG 14,2 14 14,1 15,7 14,1 14,4 12,7 12,9 na na 12 13 14,2
Pt. id.3805
Adeno 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:128 1:64
Morbilli 1:32 1:32 1:32 1:32 1:32 1:32 1:32 1:32 1:64 1:128 1:128 1:128 1:64
IgG 12,7 16,2 15,5 16,5 15,2 16,4 13,9 14 11,6 14,8 14,6 12,9 12,2
Pt. id.3806
Adeno 1:8 1:8 1:8 1:8 1:16 1:16 1:16 1:12 na na 1:16 m 1:16
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 na na <8 m <8
IgG 13,4 14 13,9 13,6 14,4 14,1 12,6 13,1 na na 12,6 m 11,3
Pt. id.3807
Adeno 1:8 1:16 1:16 1:32 1:32 1:32 1:32 1:32 na na 1:32 1:32 1:32
Morbilli 1:8 1:8 1:8 1:8 1:8 1:8 1:16 1:16 na na 1:16 1:8 1:8
IgG 14,3 15,2 16,5 15,6 15,5 16,8 15,3 18 na na 15,8 15,3 16,3
Pt. id.3808
Adeno <8 <8 <8 <8 <8 <8 <8 <8 na na < 8 < 8 < 8
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 na na < 8 < 8 < 8
IgG 12,5 15,3 13,5 13,7 12,9 14,7 12,4 14,5 na na 13,5 11,6 12,7
Pt. id.3809
Adeno 1:8 1:8 1:16 1:8 1:8 1:8 1:8 1:8 1:32 1:8 1:8 1:8 1:8
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
IgG 11,7 12,3 11,9 12 12,1 11,1 11,1 11 11,4 11,9 13,1 11,1 10,3
Pt. id.3810
Adeno 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:64 na na 1:64 1:64 1:64
Morbilli 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 na na 1:16 1:16 1:16
IgG 11,9 11,2 11 10,9 10,5 9,16 10,3 11,3 na na 11,8 12 9,13
Pt. id.3811
Adeno <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
IgG 7,8 8,51 7,56 7,83 8,9 8,07 6,06 6,39 6,11 5,37 6,39 7,82 6,68
Pt. id.3812
Adeno 1:16 1:16 1:16 1:16 1:16 1:16 1:24 1:32 1:32 1:32 1:32 1:32 1:24
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
IgG 12 11,2 12,4 12,2 11 9,69 9,95 9,69 10,6 10,9 11,4 11,5 9,59
Pt. id.3813
Adeno 1:8 1:8 1:8 1:8 1:8 1:16 1:16 1:16 na na 1:16 1:16 1:16
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 na na <8 <8 <8
IgG 11,4 12,2 11,5 11,4 11 11,3 11,3 11 na na 13 10,9 10,5
Pt. id.3814
Adeno 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 na na 1:16 1:16 1:16
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 na na <8 <8 <8
IgG 17,3 16,9 18,4 18,5 19,3 17,5 16,4 16,4 na na 16,1 13,3 10,6
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Pt. id.3815
Adeno 1:32 1:32 1:32 1:64 1:64 1:64 1:64 1:64 1:64 1:64 1:128 1:64 1:64
Morbilli 1:32 1:32 1:32 1:32 1:32 1:32 1:32 1:64 1:64 1:64 1:64 1:64 1:32
IgG 16,5 16,6 16,2 17,8 18 17,2 16,9 18,2 19 17,6 20,1 16,3 13,2
Pt. id.3816
Adeno 1:32 1:32 1:32 1:32 1:32 1:32 1:32 1:64 na na 1:64 m 1:64
Morbilli 1.8 1:8 1:8 1:8 1:8 <8 <8 <8 na na <8 m <8
IgG 13,7 14,2 14,8 14,1 13,9 11,8 10,1 10,9 na na 13,1 m 12,3
Pt. id.3817
Adeno 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:32 na na 1:32 1:32 1:32
Morbilli 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 na na 1:16 1:16 1:16
IgG 9,79 12,6 12,8 13,9 12,9 11,1 10 11,2 na na 12,7 11,6 10,8
Pt. id.3818
Adeno <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
Morbilli <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
IgG 10,6 11,4 11,9 11,6 11,3 12,2 11,6 11,4 11,6 12 10,8 10,8 9,86
Pt. id.3819
Adeno <8 <8 <8 <8 <8 <8 <8 <8 na na 8 8 8
Morbilli 1:64 1:64 1:64 1:128 1:128 1:128 1:128 1:128 na na 1:128 1:128 1:128
IgG 11,7 11,4 11,9 12,2 11,8 10,9 11 11,2 na na 13 10,5 13,7
Pt. id.3820
Adeno 1:16 1:16 1:16 1:16 1:16 1:16 1:32 1:64 na na 1:32 m 1:32
Morbilli 1:256 1:256 1:256 1:256 1:512 1:512 1:256 1:256 na na 1:256 m 1:256
IgG 16,9 17,7 17,6 17,4 18,2 16,6 18 15,4 na na 17,3 m 17,7
Pt. id.3821
Adeno <8 <8 <8 m <8 <8 <8 <8 na na <8 m m
Morbilli 1:128 1:128 1:128 m 1:128 1:128 1:128 1:256 na na 1:128 m m
IgG 14,9 14,9 15,6 m 16,1 16,1 15,9 16,2 na na 14,4 m m
Pt. id.3822
Adeno 8 8 8 8 8 8 <8 <8 <8 <8 <8 m <8
Morbilli 8 8 8 8 <8 <8 <8 <8 <8 <8 <8 m <8
IgG 14,1 15,2 15,3 15 14,1 14,3 12,3 12,7 11,9 12,8 13,4 m 12,2
Pt. id.3823
Adeno <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
Morbilli 1:32 1:32 1:32 1:32 1:32 1:64 1:64 1:64 1:128 1:128 1:256 1:128 1:64
IgG 10,7 11,3 10,7 11,3 10,8 11,6 10,9 11,3 12,2 12,9 14 10,8 8,93
Pt. id.3824
Adeno 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16 1:16
Morbilli 1:512 1:512 1:512 1:512 1:512 1:512 1:512 1:512 1:512 1:512 1:512 1:512 1:512
IgG 19,7 22,1 21,2 20,7 18,1 15,7 16,8 15,2 m m 14,9 20,9 m
Pt. id.3825
Adeno 1:32 1:16 1:16 1:16 1:16 1:16 1:32 1:32 na na 1:32 1:32 m
Morbilli 1:16 1:8 1:8 1:8 1:8 1:8 1:16 1:16 na na 1:16 1:8 m
IgG 12,4 10,7 9,13 11,1 12,3 7,25 7,16 9,82 na na 10,6 8,33 m
Pt. id.3826
Adeno <8 <8 <8 <8 <8 m <8 <8 na na <8 m m
Morbilli <8 <8 <8 <8 <8 m <8 <8 na na <8 m m
IgG 16,1 13,6 14,9 15,6 14,9 m 15,1 12,7 na na 13 m m
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Table-9b: Combined table for CFT, rubella IgG and total IgG 
 
Pt.id  Day 0 Day 8 Week 8 Week 24  Pt.id  Day 0 Day 8 Week 8 Week 24 
3803          3809         
Adeno 1:32 1:16 1:16 1:8  Adeno 1:8 1:8 1:8 1:8 
Morbilli < 8 < 8 < 8 < 8  Morbilli < 8 < 8 < 8 < 8 
Rubella 63,7 111,6 56,4 109,9  Rubella 68,8 72,9 56,8 124,8 
IgG 16,7 18,9 16,5 16,9  IgG 11,7 12 11,1 13,1 
3804         3810        
Adeno < 8 < 8 < 8 < 8  Adeno 1:64 1:64 1:64 1:64 
Morbilli 1:128 1:128 1:128 1:256  Morbilli 1:16 1:16 1:16 1:16 
Rubella 518,6 635,6 576,9 706,4  Rubella 120,8 137,5 150,3 140,3 
IgG 14,2 15,7 12,7 12  IgG 11,9 10,9 10,3 11,8 
3805          3811         
Adeno 1:64 1:64 1:64 1:64  Adeno < 8 < 8 < 8 < 8 
Morbilli 1:32 1:32 1:32 1:128  Morbilli < 8 < 8 < 8 < 8 
Rubella 224,9 256,5 193 947,7  Rubella 32,3 29,6 28,3 31,6 
IgG 12,7 16,5 13,9 14,6  IgG 7,8 7,83 6,06 6,39 
3806          3812         
Adeno 1:8 1:8 1:8 1:16  Adeno 1:16 1:16 1:24 1:32 
Morbilli < 8 < 8 < 8 < 8  Morbilli 0 0 0 0 
Rubella 215,5 157,4 229,6 165,4  Rubella 388,7 289,4 377,2 454,9 
IgG 13,4 13,6 12,6 12,6  IgG 12 12,2 9,95 11,4 
3807          3813         
Adeno 1:8 1:32 1:32 1:32  Adeno 1:8 1:8 1:16 1:16 
Morbilli 1:8 1:8 1:16 1:16  Morbilli < 8 < 8 < 8 < 8 
Rubella 67,6 54,1 62,1 88  Rubella 269,6 334 374,4 309,1 
IgG 14,3 15,6 15,3 15,8  IgG 11,4 11,4 11,3 13 
3808          3814         
Adeno < 8 < 8 < 8 < 8  Adeno 1:16 1:16 1:16 1:16 
Morbilli < 8 < 8 < 8 < 8  Morbilli < 8 < 8 < 8 < 8 
Rubella 260,5 220,7 281,9 206,9  Rubella 229,2 254,1 203,6 115,2 
IgG 12,5 13,7 12,4 13,5  IgG 17,3 18,5 16,4 16,1 
Pt.id  
Day 0 Day 8 Week 8 Week 24  Pt.id  Day 0 Day 8 Week 8 Week 24 
3815      3821     
Adeno 1:32 1:64 1:64 1:128  Adeno < 8 m < 8 < 8 
Morbilli 1:32 1:32 1:32 1:64  Morbilli 1:128 m 1:128 1:128 
Rubella 80,3 170,5 128,5 318,7  Rubella 357,8 m 466,8 350,1 
IgG 16,5 17,8 16,9 20,1  IgG 14,9 m 15,9 14,4 
3816          3822         
Adeno 1:32 1:32 1:32 1:64  Adeno 1:8 1:8 < 8 < 8 
Morbilli 1:8 1:8 < 8 < 8  Morbilli 1:8 1:8 < 8 < 8 
Rubella 101,2 100,4 61 123,7  Rubella 39,7 34,9 36,9 204,6 
IgG 13,7 14,1 10,1 13,1  IgG 14,1 15 12,3 13,4 
3817          3823         
Adeno 1:16 1:16 1:16 1:32  Adeno < 8 < 8 < 8 < 8 
Morbilli 1:16 1:16 1:16 1:16  Morbilli 1:32 1:32 1:64 1:256 
Rubella 168,6 161,9 106,7 471,3  Rubella 47,2 53,2 51,1 45,7 
IgG 9,79 13,9 10 12,7  IgG 10,7 11,3 10,9 14 
3818          3824        
Adeno < 8 < 8 < 8 < 8  Adeno 1:16 1:16 1:16 1:16 
Morbilli < 8 < 8 < 8 < 8  Morbilli 1:512 1:512 1:512 1:512 
Rubella 254,4 211,6 217,7 284,3  Rubella 2286,2 2578,7 1977,7 1663,2 
IgG 10,6 11,6 11,6 10,8  IgG 19,7 20,7 16,8 14,9 
3819          3825         
Adeno < 8 < 8 < 8 1:8  Adeno 1:32 1:16 1:32 1:32 
Morbilli 1:64 1:128 1:128 1:128  Morbilli 1:16 1:8 1:16 1:16 
Rubella 136,3 140,3 121,5 156,3  Rubella 791,1 721 655,5 1092 
IgG 11,7 12,2 11 13  IgG 12,4 11,1 7,16 10,6 
3820         3826         
Adeno 1:16 1:16 1:32 1:32  Adeno < 8 < 8 < 8 < 8 
Morbilli 256 256 256 256  Morbilli < 8 < 8 < 8 < 8 
Rubella 1142,8 1167,9 1162,1 1199,1  Rubella 209,9 945,9 1166,1 1196,2 
IgG 16,9 17,4 18 17,3  IgG 16,1 15,6 15,1 13 
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Figure 7a: Sera where there is no antibody reactivity to morbilli and adeno viruses 
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Figure 7b: Sera which did not show any or insignificant reactivity to morbilli virus 
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Figure 7c: Sera which did not show any or insignificant reactivity to adeno virus 
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Table-10: S/CO for Total anti-HCV, Dilution 1:50 in Abbott Architect system 
 
Responders 
Patient id D 1 D 3 D 7 D 8 D 14 D 29 W  8 W 12 W 16 W 20 W 24 W 36 W 48 
3803 8,73 7,6 8,75 8,42 8,49 7,1 6,19 4,82 4,89 4,14 3,77 2,08 m 
3805 12,89 12,82 12,39 12,7 12,15 12,44 11,77 11,98 11,52 10,4 11,2 9,68 9,13 
3806 10,19 11,23 10,25 10,39 9,89 9,75 9,09 8,88 na na 7,71 m 5,15 
3807 5,55 5,21 5,84 5,55 6,17 5,76 4,94 5,27 na na 2,53 1,84 1,32 
3808 6,01 6,18 6,41 6,13 5,51 6,32 4,94 5,31 na na na 2,48 1,86 
3809 5,5 5,51 5,25 5,06 5,72 4,81 4,69 5,1 5,04 4,84 4,28 3,85 3,79 
3811 7,18 7,74 6,51 6,54 6,83 5,39 5,13 4,57 3,96 3,66 3,62 2,69 1,71 
3812 9,95 9,53 10,25 9,68 8,7 8,34 6,71 7,09 5,99 5,6 5,98 3,99 2,96 
3813 6,04 6,41 5,48 5,59 4,7 5,48 5,5 5,31 na na 5,07 3,98 2,8 
3814 12,96 12,08 12,82 13,05 12,0 12,15 11,56 11,01 na na 9,19 7,19 4,81 
3815 11,87 12,83 13,39 13,18 12,24 12,18 12,09 8,95 10,36 9,9 10,26 9,09 7,22 
3816 8,61 9,27 9,76 8,1 8,27 6,75 8,59 7,42 na na 6,24 m 4,2 
3817 10,33 9,07 8,77 9,3 8,71 8,96 7,82 7,93 na na 6,6 5,64 4,91 
3818 7,76 7,94 8,11 8,16 8,48 8,85 10,4 7,51 7,36 6,72 6,5 5,01 4,42 
3819 8,44 7,83 9,01 8,78 8,75 7,87 7,87 7,6 na na 7,52 6,16 6,29 
3822 9,31 8,85 10,33 10,06 9,78 8,62 8,57 8,58 7,75 7,91 7,07 m 6,39 
3823 5,74 5,52 5,61 5,79 5,58 5,82 5,11 4,09 4,37 4,86 4,03 2,96 1,64 
3825 13,48 12,55 13,49 12,48 12,43 11,94 11,49 9,86 na na 8,16 4,8 m 
3826 12,06 11,41 11,84 11,3 10,57 m 10,57 10,93 na na 9,2 m m 
Mean 9,08 8,93 9,17 8,96 8,68 8,25 8,05 7,48 6,80 6,45 6,47 4,76 4,29 
 
Non-Responders 
Patient id D 1 D 3 D 7 D 8 D 14 D 29 W  8 W 12 W 24 W 36 W 48 
3804 11,16 10,87 11,37 12,07 11,03 10,56 9,56 9,25 9,98 10,2 9,85 
3810 3,47 3,7 3,53 3,4 3,18 2,57 3,15 2,97 2,65 3,18 2,81 
3820 3,41 5,02 5,53 6,07 5,1 5,17 4,94 4,28 4,87  m 7,75 
3821 7,38 7,48 7,83  m 8,08 7,14 7,17 6,73 7,3  m m  
3824 12,29 12,26 13,08 12,14 12,7 11,98 11,48 10,56 11,98 12,43 12,01 
Mean 7,54 7,87 8,27 8,42 8,02 7,48 7,26 6,76 7,36 8,60 8,11 
na – not applicable m – missing serum 
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Figure 8b: Total IgG and anti-HCV for responders 
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Figure 8c: Total IgG and anti-HCV for non-responders 
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Table-12a:  
Plate 1 1 2 3 4 5 6 7 8 9 10 11 12
A 0,84 1.00 0,30 0,12 0,60 0,06 0,86 1,03 0,26 0,15 0,53 0,07
B 1,03 1,03 0,27 0,12 0.64 0,05 1,02 1,04 0,30 0,16 0,66 0,07
C 0,24 0,25 0.10 0,08 0,14 0,05 0,21 0,25 0,10 0,10 0,17 0,06
D 0,30 0,24 0,09 0,08 0,15 0,05 0,24 0,27 0,10 0,09 0,17 0,06
E 0,10 0,09 0,06 0,06 0,07 0,56 0,10 0,09 0,08 0,06 0,08 0,39
F 0.10 0,09 0,05 0,05 0,07 0,15 0,10 0,10 0,06 0,06 0,08 0,14
G 0,07 0,07 0,05 0,05 0,07 0,07 0,07 0,07 0,06 0,06 0,08 0,08
H 0,07 0,06 0,05 0,05 0,07 0,06 0,06 0,07 0,06 0,07 0,06 0,08
Antigen
Conjugate
100 ng per well50 ng per well
Dilution 1:50
5 % nonfat dried milk used as blocking buffer
 
 
Table-12b: 
Plate 2 1 2 3 4 5 6 7 8 9 10 11 12
A 0,68 1,21 0,45 0,60 0,76 0,06 0,43 0,65 0.22 0.33 0,35 0.07
B 0,76 1,28 0,44 0,43 0,71 0,06 0,41 0,7 0,24 0,32 0,41 0,07
C 0,26 0,58 0,2 0,19 0,25 0,06 0,15 0,29 0,13 0,13 0,16 0,08
D 0,27 0.55 0,18 0,18 0,27 0,06 0,14 0,28 0,12 0,12 0,14 0,07
E 0,16 0,31 0,13 0,12 0,13 3,40 0,09 0,16 0,10 0,09 0,09 1,50
F 0,13 0,34 0,13 0,11 0,13 3,34 0,09 0,15 0,10 0,09 0,09 1,54
G 0,08 0,13 0,09 0,07 0,08 2,57 0,06 0,08 0,07 0,07 0,08 1,54
H 0,07 0,1 0,09 0,07 0,07 2,31 0,06 0,07 0,06 0,07 0,07 1,52
Antigen
Conjugate
20 % FBS used as blocking buffer
100 ng per well
Dilution 1:25 Dilution 1:50
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Table-12c: 
Plate 3 1 2 3 4 5 6 7 8 9 10 11 12
A 0,70 1,10 0.50 0,42 0,45 0,06 0,32 0,55 0,29 0,25 0,33 0,07
B 0,63 1,14 0,58 0.50 0,52 0,06 0,24 0,58 0,32 0,29 0,35 0,08
C 0,28 0,52 0,38 0,15 0,18 0,06 0,17 0,30 0,22 0,13 0,14 0,07
D 0,29 0,53 0,37 0,13 0,17 0,05 0,14 0.29 0,20 0,14 0,12 0,07
E 0,21 0.38 0,32 0.09 0.10 0,55 0,12 0,22 0,18 0,09 0,12 0,26
F 0,19 0,49 0,28 0,11 0.09 0,92 0,11 0,23 0,18 0,09 0,10 0,47
G 0,2 0,17 0,16 0,07 0,05 3,07 0,07 0,13 0,13 0,09 0,08 1,28
H 0,11 0,19 0,16 0,09 0,07 2,98 0,07 0,1 0,10 0,07 0,06 1,45
Antigen
Conjugate
50 ng per well
Dilution 1:25 Dilution 1:50
5 % nonfat dried milk used as blocking buffer
 
 
Table-12d: 
Plate 4 1 2 3 4 5 6 7 8 9 10 11 12
A 0,27 0,69 0,37 0,27 0,27 0,06 0,54 1,37 0,81 0,49 0.65 0.08
B 0.26 0,72 0,38 0,25 0,26 0,06 0,53 1,34 0,81 0,53 0,63 0,08
C 0,18 0,46 0,26 0,13 0,13 0,06 0,34 0,77 0,50 0,20 0,26 0,08
D 0,18 0,46 0,26 0,13 0,14 0,06 0,33 0.82 0,51 0,21 0,29 0,08
E 0,13 0,35 0,21 0,10 0,1 0,30 0,25 0,63 0,33 0,17 0,17 0,59
F 0,14 0,33 0,21 0,09 0,09 0,20 0,25 0,64 0,40 0,15 0,17 0,36
G 0,09 0,22 0,16 0,07 0,07 0,15 0,15 0,41 0,31 0,11 0,12 0,26
H 0,09 0,23 0,17 0,07 0,07 0,11 0,13 0,37 0,29 0,11 0,12 0,16
Antigen
Conjugate
100 ng per well
Undiluted conjugate-Parvo-kit Diluted 1:2, conjugate-Parvo-kit
5 % nonfat dried milk used as blocking buffer
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Table-12e: 
Plate 5 1 2 3 4 5 6 7 8 9 10 3,89 12
A 3,35 3,88 3,53 3,76 3,78 0,06 2,83 3,87 2,51 3,02 3,89 0.08
B 3,68 4,02 3,48 3,83 3,99 0,06 2,78 4,02 2,46 2,99 4,03 0,07
C 1,71 3,72 1,73 1,76 3,02 0,06 1,27 2,97 1,13 1,2 2,23 0,07
D 1,66 3,57 1,63 1,65 2,97 0,06 1,2 2,94 1,19 1,18 2,27 0,07
E 1,38 2,5 1,19 0,99 1,81 0,55 0,75 2,02 0,81 0,71 1,34 0,43
F 1,39 2,64 1,17 0,92 1,85 0,96 0,76 1,99 0,76 0,5 1,36 0,7
G 0.54 0,93 0,56 0,29 o,33 0,62 0,22 0,77 0,39 0,18 0,35 0,42
H 0,41 1,15 0,62 0,39 0,46 0,25 0,30 0,76 0,40 0,19 0,40 0,24
Antigen
Conjugate
50 ng per well
5 % nonfat dried milk used as blocking buffer
Undiluted conjugate-EBV-kit Diluted 1:2, conjugate-EBV-kit
 
 
Table-12f: 
Plate 6 1 2 3 4 5 6 7 8 9 10 11 12
0,22 0,06 0,72 0,08 0,49 0,42 0,12 0,06 0,39 0,08 0,27 0,27
P1,1:50 P3,1:1000 N1,1:50 N3,1:1000 P5,1:50 N5,1:50 P1,1:50 P3,1:1000 N1,1:50 N3,1:1000 P5,1:50 N5,1:50
0,08 0,19 0,27 0,2 0,41 0,19 0,06 0,09 0,16 0,14 0,25 0,14
P1,1:100 P4,1:50 N1,1:100 N4,1:50 P5,1:100 N5,1:100 P1,1:100 P4,1:50 N1,1:100 N4,1:50 P5,1:100 N5,1:100
0,06 0,1 0,17 0,11 0,35 0,13 0,06 0,06 0,11 0,09 0,23 0,10
P1,1:1000 P4,1:100 N1,1:1000 N4,1:100 P5,1:200 N5,1:200 P1,1:1000 P4,1:100 N1,1:1000 N4,1:100 P5,1:200 N5,1:200
0,17 0,07 0,17 0,08 0,30 0,07 0,11 0,05 0,12 0,07 0,19 0,08
P2,1:50 P4,1:1000 N2,1:50 N4,1:1000 P5,1:400 N5,1:400 P2,1:50 P4,1:1000 N2,1:50 N4,1:1000 P5,1:400 N5,1:400
0,09 0,30 0,09 0,40 0,24 0,05 0,07 0,07 0,08 0,25 0,16 0,07
P2,1:100 P5,1:50 N2,1:100 N5,1:50 P5,1:800 Blank P2,1:100 P5,1:50 N2,1:100 N5,1:50 P5,1:800 Blank
0,07 0,16 0,07 0,18 0,16 0,05 0,06 0,05 0,07 0,13 0,13 0,07
P2,1:1000 P5,1:100 N2,1:1000 N5,1:100 P5,1:1600 Blank P2,1:1000 P5,1:100 N2,1:1000 N5,1:100 P5,1:1600 Blank
0,10 0,11 0,20 0,12 0,13 0,05 0,07 0,05 0,14 0,10 0,11 0,07
P3,1:50 P5,1:1000 N3,1:50 N5,1:1000 P5,1:3200 Blank P3,1:50 P5,1:1000 N3,1:50 N5,1:1000 P5,1:3200 Blank
0,07 0,05 0,10 0,05 0,09 0,05 0,05 0,05 0,08 0,05 0,09 0,08
P3,1:100 Blank N3,1:100 Blank P5,1:6400 Blank P3,1:100 Blank N3,1:100 Blank P5,1:6400 Blank
Antigen
Conjugate
E
100 ng per well
Dilution 1:50 Dilution 1:100
F
G
H
A
B
C
D
Each well has infomation of OD value and serum dilution.  P = positiv serum, N = negative serum
Super Block blocking buffer
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Table-12g: 
Plate 7 1 2 3 4 5 6 7 8 9 10 11 12
A 0,20 0,08 0,19 0,25 0,32 0,15 0,11 0,06 0,13 0,14 0,19 0.12
B 0,08 0,30 0,17 0,3 0,31 0,14 0,06 0,16 0,11 0,18 0,19 0,11
C 0,06 0,13 0,13 0,27 0,32 0,12 0,06 0,08 0,09 0,17 0,19 0.09
D 0,36 0,08 0,21 0,21 0,31 0,07 0,17 0,06 0,15 0,14 0,19 0,07
E 0,16 0,29 0,24 0,12 0,26 0,05 0,08 0,15 0,14 0,10 0,15 0,06
F 0,09 0,16 0,18 0,13 0,18 0,05 0,06 0,08 0,11 0,10 0,13 0,06
G 0,26 0,09 0,17 0,12 0,14 0,05 0,13 0,07 0,11 0,10 0,10 0,07
H 0,13 0,05 0,20 0,05 0,10 0,08 0,07 0,05 0,12 0,06 0,08 0,07
Antigen
Conjugate
Sera and dilutions see plate 6
Super Block blocking buffer
50 ng per well
Dilution 1:50 Dilution 1:100
 
 
 
 
 
